









Markets
/
Stocks
/
nasdaq-azn
/

AstraZeneca PLC

AZN

187.540USD

+3.470+1.89%

Market hours （ET）Quotes delayed by 15 min

581.64BMarket Cap

28.43P/E TTM



AstraZeneca PLC

187.540

+3.470+1.89%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of AstraZeneca PLC

Currency: USD Updated: 2026-03-24

Key Insights

AstraZeneca PLC's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 208.20.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

AstraZeneca PLC's Score

Industry at a Glance

Industry Ranking

26 / 157

Overall Ranking

95 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

AstraZeneca PLC Highlights

StrengthsRisks

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology firm headquartered at the Cambridge Biomedical Campus in Cambridge, UK. The company boasts a diverse portfolio of products aimed at treating major diseases in areas such as oncology, cardiovascular health, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation.

Founded in 1999 through the merger of Swedish Astra AB and British Zeneca Group, it includes offerings for both primary and specialty care, coverage for rare diseases, and maintains a strong global presence across various regions. Since the merger, AstraZeneca has consistently ranked among the largest pharmaceutical companies worldwide and has executed numerous corporate acquisitions, such as Cambridge Antibody Technology, MedImmune, Spirogen, and Definiens. Its research and development efforts are concentrated in three strategic centers: Cambridge in the UK, Gothenburg in Sweden, and Gaithersburg in Maryland, US.

AstraZeneca’s corporate lineage can be traced back to 1913, when Astra AB was established by a significant group of physicians and pharmacists in Södertälje. Throughout the 20th century, Astra AB evolved into Sweden's largest pharmaceutical company. Its British counterpart, Zeneca PLC, was created in 1993 when ICI divested its pharmaceuticals division; six years later, Astra AB and Zeneca PLC merged, designating the United Kingdom as the headquarters.

AstraZeneca's primary listing is on the London Stock Exchange, where it is part of the FTSE 100 Index, alongside a secondary listing on Nasdaq Stockholm. It is also traded on the American Nasdaq and is included in the Nasdaq-100 index. AstraZeneca ranks among the pharmaceutical companies globally with one of the highest market capitalizations.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 28.22% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 58.74B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 68.32%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 68.32%.

Undervalued

The company’s latest PE is 28.16, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 518.15M shares, increasing 0.38% quarter-over-quarter.

Held by Brandes Investmen

Star Investor Brandes Investmen holds 1.08K shares of this stock.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

208.200

Target Price

+13.40%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-24

The current financial score of AstraZeneca PLC is 8.56, ranking 47 out of 157 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 15.50B, representing a year-over-year increase of 4.11%, while its net profit experienced a year-over-year increase of 55.07%.

Score

Industry at a Glance

Previous score

8.56

Change



Financials

5.81

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.22

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.25

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

AstraZeneca PLC's Company Valuation

Currency: USD Updated: 2026-03-24

The current valuation score of AstraZeneca PLC is 8.13, ranking 30 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 28.16, which is 140.73% below the recent high of 67.80 and 8.78% above the recent low of 25.69.

Score

Industry at a Glance

Previous score

8.13

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 26/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-24

The current earnings forecast score of AstraZeneca PLC is 8.67, ranking 13 out of 157 in the Pharmaceuticals industry. The average price target is 99.00, with a high of 232.41 and a low of 67.00.

Score

Industry at a Glance

Previous score

8.50

Change

0.17

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

208.200

Target Price

+13.40%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

AstraZeneca PLC

AZN

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-24

The current price momentum score of AstraZeneca PLC is 6.86, ranking 48 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 203.01 and the support level at 175.47, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.76

Change

0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-7.486

Neutral

RSI(14)

48.774

Neutral

STOCH(KDJ)(9,3,3)

20.589

Neutral

ATR(14)

4.053

Low Volatility

CCI(14)

-125.137

Sell

Williams %R

80.210

Oversold

TRIX(12,20)

0.077

Sell

StochRSI(14)

45.392

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

186.160

Buy

MA10

188.981

Sell

MA20

194.837

Sell

MA50

167.645

Buy

MA100

128.696

Buy

MA200

102.740

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-24

The current institutional shareholding score of AstraZeneca PLC is 3.00, ranking 93 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 17.29%, representing a quarter-over-quarter decrease of 0.27%. The largest institutional shareholder is PRIMECAP Management, holding a total of 39.86M shares, representing 1.28% of shares outstanding, with 1.99% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Wellington Management Company, LLP

32.30M

-5.93%

Risk Assessment

Currency: USD Updated: 2026-03-24

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of AstraZeneca PLC is 9.88, ranking 3 out of 157 in the Pharmaceuticals industry. The company's beta value is 1.00. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.